Regenerating Torn Cartilage
A new biomaterial developed by Cartilix could dramatically improve the success rate of knee-cartilage repair surgery, making the procedure more accessible to patients with bad knees.
Scientists Identify New Bone Protecting Protein
Researchers at the Universities of Manchester and Oxford have identified a naturally occurring protein molecule that not only protects against inflammation but also actively inhibits bone erosion in those affected by disease.
A New Cell Therapy Technique with Demonstrated Efficacy in Chronic, Localized and Stable Forms of Vitiligo
Specialists at the University Hospital of Navarra have managed to repigment certain areas of the body affected by vitiligo by transplanting epidermal cells from a pigmented area of the patient’s skin to other areas of the same patient which are depigmented.
Pioneering Heart Disease Trials Call for More Patients
Doctors at Barts and The London are calling for more patients to come forward to take part in the UK’s first large scale adult stem cell trial for heart disease.
Utah Tests May Lead to Stem Cell Treatment of Kidney Failure
Intermountain Medical Center and AlloCure, a Utah-based biotech company, have teamed up to test AlloCure’s patented cells in patients who have had open-heart surgery.
Stratatech Successfully Completes Clinical Trial of StrataGraft(R) Skin Substitute
Stratatech Corp. recently announced that it has successfully completed the multi-center, 15-patient clinical trial of its StrataGraft(R) living human skin substitute.
Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
Bioheart, Inc. recently announced that 35 of the leading U.S. Heart Failure Centers have engaged in Bioheart’s Phase II/III MARVEL(1) Trial of myogenic cells for treating advanced heart failure.
ABSTRACTS, REVIEWS AND SPECIAL REPORTS
MUC1* Mediates the Growth of Human Pluripotent Stem Cells
This study reports that MUC1*, a transmembrane cleavage product, acts as a growth factor receptor on undifferentiated human embryonic stem cells.
Wnt3a Deficiency Irreversibly Impairs Hematopoietic Stem Cell Self-Renewal and Leads to Defects in Progenitor Cell Differentiation
This study shows that Wnt3a signaling not only provides proliferative stimuli, such as for immature thymocytes, but also regulates cell fate decisions of HSC during hematopoiesis.
What to Do with Leftover Embryos in Fertility Clinics?
The majority of infertility patients are in favor of using left-over embryos for stem cell research and would also support selling left-over embryos to other couples, according to a recent survey.
Cell Process Developer
R&D Manager-Cell Technologies
Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.